Clinical Trial

Neurobiological and Genomic Predictors of Relapse in Depression

Study acronym: MDD
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters. The main questions it aims are: 1. When patients with depression treated with antidepressants, does their brain activity also become normal? If so, 2. Then, can we stop the antidepressant treatment and expect minimum repeat of depression? The participants who receive a specific antidepressant treatment will be asked to: * Undergo quantitative electroencephalography (qEEG), * Record Event-related potential (ERP), * Record Sleep EEG * Answer Hamilton Depression Rating Scale question their psychiatrists asked * Give blood sample for genetic analysis * Repeat the above mentioned procedures for at least 3 times during their treatment period. Researchers will compare the results of patients with the results of healthy controls.
Trial Details
NCT Number NCT07328373
Lead Sponsor Mehmet Kemal Arikan
Conditions Healthy, Major Depressive Disorder (MDD)
Enrollment 204 participants
Start Date 2025-01-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-09